-+ 0.00%
-+ 0.00%
-+ 0.00%

NKGEN BIOTECH’S POSITIVE PHASE 1 CLINICAL DATA IN MODERATE ALZHEIMER’S DISEASE ADVANCES TROCULEUCEL INTO PHASE 2 WITH FIRST PATIENT DOSED IN PHASE 1/2A TRIAL

Reuters·09/12/2024 12:05:59
Listen to the news
NKGEN BIOTECH’S POSITIVE PHASE 1 CLINICAL DATA IN MODERATE ALZHEIMER’S DISEASE ADVANCES TROCULEUCEL INTO PHASE 2 WITH FIRST PATIENT DOSED IN PHASE 1/2A TRIAL